Retatrutide, the triple agonist, reached up to 24.2% in phase 2 and up to 28.7% in TRIUMPH-4
PROVIDES IMMUNE SUPPORT
In TRIUMPH-2, which enrolled adults with obesity or overweight and type 2 diabetes, participants receiving the highest 12 mg dose lost an average of 20.8% of their body weight during 80 weeks, compared with 3.2% for placebo
Neuropharmacology 128, 142151
Comparison with Metformin and SGLT2 Inhibitors Metformin: Often a first-line diabetes drug, but less effective for weight loss
However, some people report a complete loss of appetite As tirzepatide targets two hormones and retatrutide targets three, it may mean that tirzepatide is easier to tolerate at low doses, but more testing and data is needed